Jinghua Pharmaceutical released its 2026 interim report, with total operating revenue of 755 million yuan, up 3.19% year-on-year, and net profit attributable to the parent of 136 million yuan, up 4.20% year-on-year. Net cash inflow from operating activities was 111 million yuan, the asset-liability ratio was 10.68%, gross margin was 54.26%, ROE was 4.81%, and diluted earnings per share was 0.17 yuan. The number of shareholders was 76,500, and the top ten shareholders held 40.02% of the total share capital.
Nantong Jinghua Pharmaceutical Co LtdNet profit up 4.20% year-on-year, beating expectations.
